Dyronib 20 Tablets (Dasatinib Tablets 20 mg)

Dyronib 20 Tablets is a branded oncology oral formulation containing dasatinib, a tyrosine kinase inhibitor used in regulated cancer treatment settings. Manufactured for professional pharmaceutical distribution, Dyronib 20 Tablets are supplied in accordance with international quality and compliance requirements. AmeriDrugs supplies this product for export to licensed importers, distributors, hospitals, and pharmacies operating within approved regulatory frameworks.

Active Ingredient (API + Strength)

• Active Pharmaceutical Ingredient: Dasatinib

• Strength: 20 mg per tablet

• Dosage Form: Film-coated tablet

Therapeutic Use (Informational, Non-Advisory)
Dasatinib is classified as a tyrosine kinase inhibitor and is used within approved oncology treatment protocols for specific hematological malignancies, including certain types of leukemia, as determined by regulatory authorities. Dyronib 20 Tablets are supplied strictly for use under locally approved clinical guidelines. This information is provided solely for product identification and regulatory clarity and does not constitute medical advice or treatment recommendations.

Dosage Form & Route of Administration

• Dosage Form: Oral solid dosage (tablet)

• Route of Administration: Oral

• Prescription Status: Prescription-only medicine

• Intended for dispensing through regulated pharmaceutical and healthcare channels

Quality & Manufacturing Standards
Dyronib 20 Tablets are manufactured in compliance with current Good Manufacturing Practices (GMP) and applicable pharmacopeial standards. Production processes include validated controls to ensure uniformity, stability, and batch consistency. Each batch undergoes quality testing aligned with international regulatory and export requirements.

Packaging Information (Export-Oriented)

• Primary Packaging: Blister strips

• Pack Size: 60 tablets per box

• Secondary Packaging: Printed carton with regulatory-compliant labeling

• Packaging suitable for international pharmaceutical logistics and distribution

Target Buyers

• Licensed pharmaceutical importers and distributors

• Oncology hospitals and specialty treatment centers

• Retail and wholesale pharmacies operating under prescription regulations

• Government and private healthcare procurement agencies

• International distributors specializing in oncology oral formulations

Regulatory & Compliance Note
Dyronib 20 Tablets is a prescription-only oncology medicine intended for regulated pharmaceutical distribution. Not for direct consumer self-use. Supply is subject to import authorization, local drug regulatory approvals, and applicable healthcare compliance requirements in the destination country. AmeriDrugs follows international export compliance standards and supports required regulatory documentation for global markets.